These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 37291458)

  • 1. A computational and laboratory approach for the investigation of interactions of peptide conjugated natural terpenes with EpHA2 receptor.
    Goncalves BG; Banerjee IA
    J Mol Model; 2023 Jun; 29(7):204. PubMed ID: 37291458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An investigation of binding interactions of tumor-targeted peptide conjugated polyphenols with the kinase domain of ephrin B4 and B2 receptors.
    Mitchell SM; Heise RM; Murray ME; Lambo DJ; Daso RE; Banerjee IA
    Mol Divers; 2024 Apr; 28(2):817-849. PubMed ID: 36847923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular dynamics, MMGBSA, and docking studies of natural products conjugated to tumor-targeted peptide for targeting BRAF V600E and MERTK receptors.
    Lambo DJ; Lebedenko CG; McCallum PA; Banerjee IA
    Mol Divers; 2023 Feb; 27(1):389-423. PubMed ID: 35505173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering nanomolar peptide ligands that differentially modulate EphA2 receptor signaling.
    Gomez-Soler M; Petersen Gehring M; Lechtenberg BC; Zapata-Mercado E; Hristova K; Pasquale EB
    J Biol Chem; 2019 May; 294(22):8791-8805. PubMed ID: 31015204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular dynamics simulations, docking and MMGBSA studies of newly designed peptide-conjugated glucosyloxy stilbene derivatives with tumor cell receptors.
    Rico MI; Lebedenko CG; Mitchell SM; Banerjee IA
    Mol Divers; 2022 Oct; 26(5):2717-2743. PubMed ID: 35037187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An ephrin mimetic peptide that selectively targets the EphA2 receptor.
    Koolpe M; Dail M; Pasquale EB
    J Biol Chem; 2002 Dec; 277(49):46974-9. PubMed ID: 12351647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targefrin: A Potent Agent Targeting the Ligand Binding Domain of EphA2.
    Baggio C; Udompholkul P; Gambini L; Pellecchia M
    J Med Chem; 2022 Nov; 65(22):15443-15456. PubMed ID: 36331527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico studies of interactions of peptide-conjugated cholesterol metabolites and betulinic acid with EGFR, LDR, and N-terminal fragment of CCKA receptors.
    Bashant MM; Mitchell SM; Hart LR; Lebedenko CG; Banerjee IA
    J Mol Model; 2021 Dec; 28(1):16. PubMed ID: 34961887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conformational Clamping by a Membrane Ligand Activates the EphA2 Receptor.
    Westerfield JM; Sahoo AR; Alves DS; Grau B; Cameron A; Maxwell M; Schuster JA; Souza PCT; Mingarro I; Buck M; Barrera FN
    J Mol Biol; 2021 Sep; 433(18):167144. PubMed ID: 34229012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective Tumor Targeting by EphA2-Agonist-Biotin-Streptavidin Conjugates.
    Udompholkul P; Baggio C; Gambini L; Sun Y; Zhao M; Hoffman RM; Pellecchia M
    Molecules; 2021 Jun; 26(12):. PubMed ID: 34204178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and analysis of EphA2-SAM peptide ligands: A multi-disciplinary screening approach.
    Mercurio FA; Di Natale C; Pirone L; Marasco D; Calce E; Vincenzi M; Pedone EM; De Luca S; Leone M
    Bioorg Chem; 2019 Mar; 84():434-443. PubMed ID: 30576907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors.
    Noberini R; Koolpe M; Peddibhotla S; Dahl R; Su Y; Cosford ND; Roth GP; Pasquale EB
    J Biol Chem; 2008 Oct; 283(43):29461-72. PubMed ID: 18728010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and bioevaluation of an EphA2 receptor-based targeted delivery system.
    Barile E; Wang S; Das SK; Noberini R; Dahl R; Stebbins JL; Pasquale EB; Fisher PB; Pellecchia M
    ChemMedChem; 2014 Jul; 9(7):1403-12. PubMed ID: 24677792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and investigation of interactions of novel peptide conjugates of purine and pyrimidine derivatives with EGFR and its mutant T790M/L858R: an in silico and laboratory study.
    Hunt HL; Goncalves BG; Biggs MA; Rico MI; Murray ME; Lebedenko CG; Banerjee IA
    Mol Divers; 2024 Dec; 28(6):3683-3711. PubMed ID: 38240950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring a Potential Optimization Route for Peptide Ligands of the Sam Domain from the Lipid Phosphatase Ship2.
    Vincenzi M; Mercurio FA; La Manna S; Palumbo R; Pirone L; Marasco D; Pedone EM; Leone M
    Int J Mol Sci; 2024 Oct; 25(19):. PubMed ID: 39408946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting EphA2-Sam and Its Interactome: Design and Evaluation of Helical Peptides Enriched in Charged Residues.
    Mercurio FA; Marasco D; Di Natale C; Pirone L; Costantini S; Pedone EM; Leone M
    Chembiochem; 2016 Nov; 17(22):2179-2188. PubMed ID: 27763725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural investigation of a C-terminal EphA2 receptor mutant: Does mutation affect the structure and interaction properties of the Sam domain?
    Mercurio FA; Costantini S; Di Natale C; Pirone L; Guariniello S; Scognamiglio PL; Marasco D; Pedone EM; Leone M
    Biochim Biophys Acta Proteins Proteom; 2017 Sep; 1865(9):1095-1104. PubMed ID: 28602916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity relationship analysis of peptides targeting the EphA2 receptor.
    Mitra S; Duggineni S; Koolpe M; Zhu X; Huang Z; Pasquale EB
    Biochemistry; 2010 Aug; 49(31):6687-95. PubMed ID: 20677833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-Based Design of Novel EphA2 Agonistic Agents with Nanomolar Affinity in Vitro and in Cell.
    Gambini L; Salem AF; Udompholkul P; Tan XF; Baggio C; Shah N; Aronson A; Song J; Pellecchia M
    ACS Chem Biol; 2018 Sep; 13(9):2633-2644. PubMed ID: 30110533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological and structural characterization of glycosylation on ephrin-A1, a preferred ligand for EphA2 receptor tyrosine kinase.
    Ferluga S; Hantgan R; Goldgur Y; Himanen JP; Nikolov DB; Debinski W
    J Biol Chem; 2013 Jun; 288(25):18448-57. PubMed ID: 23661698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.